<DOC>
	<DOC>NCT02107313</DOC>
	<brief_summary>This study is designed to determine the pharmacokinetic (PK) profile of a single oral dose of PBT2 administered to healthy volunteers in the presence and absence of food.</brief_summary>
	<brief_title>Phase 1 Study to Determine the Effects of Food on the Pharmacokinetic Profile of PBT2</brief_title>
	<detailed_description>The study will be conducted in 2 dosing periods, with participants being randomised to receive PBT2 250 mg with or without food in the first dosing period, followed by a 7 day washout period before receiving the opposite fed/fasted condition to that allocated in the first dosing period. Pharmacokinetic samples will be collected during each dosing period, along with safety monitoring assessments.</detailed_description>
	<criteria>Healthy male or females with a BMI between 19 and 30kg/m2 No clinically significant abnormalities Exposure to medications/drugs that interfere with metabolism of PBT2 including drugs that inhibit or induce CYP1A2) Use of caffeinecontaining beverages, supplements or alcohol within 72 hours of study entry Significant history of depression or other psychiatric illness Surgical or medical conditions which could significantly alter drug absorption, distribution, metabolism or excretion unable to swallow capsules</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>